What are the limitations of the men1 clinical diagnostic criteria?

While the men1 clinical diagnostic criteria is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the men1 clinical diagnostic criteria to ensure safe bedside use and optimal diagnostic accuracy.

How does the men1 clinical diagnostic criteria compare to other Endocrinology scores?

The men1 clinical diagnostic criteria is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the men1 clinical diagnostic criteria free to use?

Yes. OpiCalc provides the men1 clinical diagnostic criteria completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

Men1 clinical diagnostic criteria Score and Guidance

CLINICAL REFERENCE

CLINICAL INSIGHT

When to Use

When to Screen

Patients with 2 or more of the "Three P's" (Parathyroid, Pituitary, Pancreas).
Patients with a family history of MEN1 and an associated tumor.
Evaluating unusual clusters of endocrine tumors (e.g., gastrinoma + prolactinoma).
Primary hyperparathyroidism occurring before age 40.

CLINICAL INSIGHT

How it Works

1. Clinical Diagnosis

The presence of 2 or more of the main MEN1-associated tumors (parathyroid adenoma/hyperplasia, enteropancreatic/GEP-NET, or pituitary adenoma).

2. Familial Diagnosis

The presence of 1 of the main MEN1-associated tumors in a first-degree relative of a patient with a clinical diagnosis of MEN1.

3. Genetic Diagnosis

The identification of a germline MEN1 mutation in an individual who may or may not (yet) have developed clinical or biochemical features.

CLINICAL INSIGHT

Practical Pearls

The First P

Primary hyperparathyroidism is the most common and often initial manifestation of MEN1, occurring in > 95% of patients by age 40–50.

Surveillance Checklist

Annual Calcium and PTH starting at age 5–10.
Annual Gastrin, Prolactin, and Chromogranin A.
MRI of Pituitary every 3-5 years.
CT/MRI of Abdomen (pancreas search) every 1-3 years.

CLINICAL INSIGHT

Evidence Base

Primary Source

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

Thakker RV, Newey PJ, et al.J Clin Endocrinol Metab2012

When to Use

When to Screen

How it Works

1. Clinical Diagnosis

2. Familial Diagnosis

3. Genetic Diagnosis

Practical Pearls

The First P

Surveillance Checklist

Evidence Base

Primary Source

MEN1 Clinical Diagnostic Criteria

Unlikely / Screen

When to Use

When to Screen

How it Works

1. Clinical Diagnosis

2. Familial Diagnosis

3. Genetic Diagnosis

Practical Pearls

The First P

Surveillance Checklist

Evidence Base

Primary Source

MEN1 Clinical Diagnostic Criteria

Unlikely / Screen

Clinical Evidence and Methodology

When to Use

When to Screen

How it Works

1. Clinical Diagnosis

2. Familial Diagnosis

3. Genetic Diagnosis

Practical Pearls

The First P

Surveillance Checklist

Evidence Base

Primary Source

MEN1 Clinical Diagnostic Criteria

Unlikely / Screen

Clinical Evidence and Methodology

When to Use

When to Screen

How it Works

1. Clinical Diagnosis

2. Familial Diagnosis

3. Genetic Diagnosis

Practical Pearls

The First P

Surveillance Checklist

Evidence Base

Primary Source

MEN1 Clinical Diagnostic Criteria

Unlikely / Screen